Mr. Podlesak joined Domain Associates as a partner in 2007. Prior to Domain, Mr. Podlesak served as the chief executive officer and a member of the board of directors of Cerexa, Inc., which became a wholly–owned subsidiary of Forest Laboratories after Mr. Podlesak led the growth and sale of the company to Forest. Additionally, Mr. Podlesak served as the president and chief executive officer and as a member of the board of directors of Peninsula Pharmaceuticals, and after building the company, led the sale of Peninsula to Johnson and Johnson. Mr. Podlesak was also chief executive officer, founder and board member of Calixa Therapeutics, which was acquired by Cubist, and chairman of Corthera, which was acquired by Novartis AG.

Earlier in his career, Mr. Podlesak served as senior vice president, head of the North American business unit and member of the pharmaceutical executive committee and global leadership team at Novartis AG. Mr. Podlesak also served as vice president and head of the CEC division of Allergan, Inc., and as member of Allergan's North American and global management team. Mr. Podlesak spent the first ten years of his career with SmithKline Beecham (now GlaxoSmithKline plc).

In addition to Syndax, Mr. Podlesak is currently serving as the chairman of the board at Adynxx and Regado Biosciences. Mr. Podlesak received a bachelor’s degree in business administration from Western Illinois University and an M.B.A. degree from Pepperdine University.

Ms. Morris was most recently the chief executive officer and member of the board of directors for Affymax, Inc., a biopharmaceutical company located in Palo Alto, Calif., which was spun out of GlaxoSmithKline (GSK) in 2001 to develop a pipeline of synthetic peptide-based drug candidates for the treatment of anemia in dialysis patients. During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda and an Initial Public Offering of $90 million. She also raised private C and D rounds of $100 million.

Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development.

In addition to Syndax, Ms. Morris serves on the board of directors of BIO, Neovacs, MediciNova and the Foundation for Research and Development, Medical University of South Carolina. She received her bachelor’s degree in biology and chemistry from Carlow College.

Dr. Kamdar joined Domain Associates in 2005 and became partner in 2011. Before joining Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Prior to MPM she was a research director at Novartis where she built and led a research team that focused on the biology, genetics and genomics of model organisms to uncover small molecules that modulated signaling pathway networks. Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small molecule discovery with an initial focus on anti-infectives and oncology.

In addition to Syndax, Dr. Kamdar is a board member at Lithera, Obalon Therapeutics, ROX Medical, Sonexa Therapeutics, Tandem Diagnostics and Tragara Pharmaceuticals and an advisory board member at Achaogen, aTyr Pharma, and SkinMedica. She also serves as an advisory board member to Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine and as an advisory board member for Evolvence India Life Sciences Fund, a private equity fund providing growth capital to Indian pharmaceutical and biotechnology companies.

Dr. Kamdar is the author of 11 papers as well as an inventor on seven patents. She received her bachelor’s degree from Northwestern University and her Ph.D. from Emory University.

Mr. Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He has assembled a team of investment, biotechnology and medical experts who manage over $350 million and oversee investments in more than 40 portfolio companies. Prior to founding Pappas Ventures in 1994, Art held senior level leadership positions at several multinational pharmaceutical companies, including being the CEO of international operations. In addition to leading operations, he was responsible for the development, licensing and launch of a number of key global products. He was an executive member of the board of directors of Glaxo Holdings plc, for which he was the chief executive responsible for international operations including research, development and manufacturing. Art previously was Vice President of Commercial Operations for Abbott International Ltd., and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. In addition to Syndax, other companies for which he currently serves as a director include: Afferent Pharmaceuticals, CardioDx, CeNeRx BioPharma and TyRx Pharma. He was the founding CEO and is currently the chairman of CoLucid Pharmaceuticals.

Dr. Luke Evnin focuses on global healthcare venture capital investing for MPM Capital. He co-founded MPM Capital's asset management business in 1997 and established the San Francisco office for the firm in 1999. Prior to joining MPM, Dr. Evnin was at Accel Partners for over seven years including four as a general partner. He was involved in biopharmaceutical, medical device and healthcare service companies for several of Accel's funds. Dr. Evnin currently serves as a director of Enteromedics, Inc. (ETRM) and Pacira (PCRX), publicly-traded companies, as well as private companies, NeuroTherapeutics Pharma, Inc. and Oxagen Limited. Dr. Evnin earned his Ph.D. in the department of biochemistry at the University of California-San Francisco, and received his A.B. in molecular biology magna cum laude from Princeton University.